logo
Plus   Neg
Share
Email

Sandoz To Invest EUR 150 Mln In Austrian Facility To Strengthen Antibiotics Manufacturing

Sandoz, Novartis AG's (NVS) generics and biosimilars division, announced Monday plans for a joint investment with Austrian federal government for large-scale manufacture of active ingredients for penicillin products. The deal would strengthen antibiotics manufacturing in Europe.

Sandoz intends to invest more than 150 million euros over the next five years. The Austrian federal government would contribute or coordinate public funding totaling approximately 50 million euros towards the total investment.

Under the deal, the company plans to strengthen the long-term competitiveness of its integrated antibiotic manufacturing operations at Kundl facility in Austria, developing and introducing innovative manufacturing technology for both active pharmaceutical ingredients or APIs and finished dosage forms or FDFs.

The government funding would primarily support new process technology to produce API for penicillin products at Kundl. Sandoz would commit to related penicillin API production in Europe for the next 10 years, despite fierce global price competition, particularly from China.

The joint plan is subject to formal approvals by both parties. Sandoz and the Austrian government anticipate a formal closing of the agreement before the end of the year.

The deal is part of Austrian federal government's efforts to increase European-based production of essential medicines.

Sandoz noted that it produces enough penicillin products at Kundl to potentially meet all current Europe-wide demand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT